Apatinib in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma: A Phase II, Open-Label, Single-Arm, Prospective Study

Apatinib in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma: A Phase II, Open-Label, Single-Arm, Prospective Study

Xinran Ma,* Ling Li,* Lei Zhang, Xiaorui Fu, Xin Li, Xinhua Wang, Jingjing Wu, Zhenchang Sun, Xudong Zhang, Xiaoyan Feng, Yu Chang, Zhiyuan Zhou, Feifei Nan, Jieming Zhang, Zhaoming Li, Mingzhi Zhang Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Lymphoma Diagnosis an...

Full description

Bibliographic Details
Main Authors: Ma X, Li L, Zhang L, Fu X, Li X, Wang X, Wu J, Sun Z, Zhang X, Feng X, Chang Y, Zhou Z, Nan F, Zhang J, Li Z, Zhang M
Format: Article
Language:English
Published: Dove Medical Press 2020-01-01
Series:Drug Design, Development and Therapy
Subjects:
apatinib
relapsed or refractory diffuse large b-cell lymphoma
vegfr-2
efficacy
safety
Online Access:https://www.dovepress.com/apatinib-in-patients-with-relapsed-or-refractory-diffuse-large-b-cell--peer-reviewed-article-DDDT

Internet

https://www.dovepress.com/apatinib-in-patients-with-relapsed-or-refractory-diffuse-large-b-cell--peer-reviewed-article-DDDT

Similar Items